IPOs With Potential...
Health Care: Drugs
Celldex Therapeutics Inc. (CLDX: NASDAQ)
$5.20 0.01 | 0.19%
02/09/12 - 03:59 PM ET
280.02K / 308.70K
Vol / Avg. Vol:5.14 / 5.19
Open / Prev. Close:5.09 - 5.25
Today's Range:2.05 - 5.66
52 Wk Range:99.62%
Performance YTD:TheStreet Rating:
Portfolios with CLDX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- User3rdwavemedia Portfolio 1
- UserSUPRATRADE 7 Top Stocks for...
- UserASCO 2010
- UserSolstock
- UserCaroline's picks
- UserDec 2009
- UserSUPRATRADE-2609091346
- ContributorBarron's Activist Stocks 7-...
Latest CLDX Headlines from TheStreet
- The Next Big Thing in Biotech: BIO CEO Conference
02.10.12 | 05:02 am - Friday's Top 10 Articles, Videos on TheStreet 01.20.12 | 02:01 pm
- Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger 01.20.12 | 05:01 am
- More Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
- J.P. Morgan Biotech Confab Live Chat 01.10.12 | 06:01 pm
- Biotech Stock Mailbag: Most Important Events for 2012 12.23.11 | 06:12 am
- Celldex Stock Gaps Down On Today's Open (CLDX) 05.18.11 | 09:05 am
- Coldwater Creek: After-Hours Trading 05.17.11 | 09:05 pm
- Biotech Stock Mailbag: Cyclacel Pharma 10.08.10 | 07:10 am
- Celldex Therapeutics Soars on Data 10.05.10 | 12:10 pm
Press Releases for CLDX
- Celldex Therapeutics To Participate On Therapeutic Workshop Panel At The BIO CEO & Investor Conference - Business Wire 02.09.12 | 09:02 am
- Celldex Therapeutics To Host Research And Development Day Highlighting Oncology Pipeline - Business Wire 01.18.12 | 12:01 pm
- Celldex Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of CDX-301 - Business Wire 01.17.12 | 08:01 am
- Celldex Initiates A Phase 2 Study Of Rindopepimut In Patients With Recurrent Glioblastoma Including Avastin® Naive And Refractory Populations - Business Wire 01.04.12 | 08:01 am
- Celldex Completes Accrual Of CDX-011 Phase 2b “EMERGE” Study In Advanced Breast Cancer - Business Wire 12.21.11 | 08:12 am
- Celldex Therapeutics Presents Novel Preclinical Data On CDX-1127 At The American Society Of Hematology Meeting In San Diego - Business Wire 12.12.11 | 08:12 am
- Celldex Initiates ACT IV, A Pivotal International Phase 3 Trial Of Rindopepimut In Patients With Glioblastoma - Business Wire 12.01.11 | 08:12 am
- Celldex Therapeutics Reports Positive Mature Survival Data From Rindopepimut Phase 2 Brain Cancer Study At SNO 2011 - Business Wire 11.21.11 | 08:11 am
- Celldex Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of CDX-1127 - Business Wire 11.08.11 | 08:11 am
- Celldex Reports Third Quarter 2011 Financial Results - Business Wire 11.02.11 | 07:11 am
Partner Headlines for CLDX
- 10 Biotech Stocks With 100% Upside In 2012: Part One - Seeking Alpha 02.09.12 | 10:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- Biopharma Stocks To Watch This Week - Seeking Alpha 01.19.12 | 09:01 am
- Why ImmunoCellular Therapeutics Is Different - Seeking Alpha 01.11.12 | 08:01 am
- Wedbush Maintains Outperform, $6 PT on Celidex Therapeutics - Benzinga 12.28.11 | 09:12 am
- 20 Smart Money Stock Picks Trading Under $5 - Seeking Alpha 11.03.11 | 07:11 am
- 16 Stocks Under $5 Being Bought Up By Insiders And The Smart Money - Seeking Alpha 09.16.11 | 05:09 pm
- Celldex's Vaccine Gets a Boost - Seeking Alpha 08.08.11 | 09:08 am
- Celldex: Risks Involved, But Set for a Transformational Year - Seeking Alpha 06.20.11 | 06:06 am
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
